Components of the Multiple Sclerosis Functional Composite
The MSFC is a composite of three objective quantitative tests of neurologic function that were identified as being important in MS, including ambulatory function, arm function and cognitive function (see Table 1 ). 17 The Timed 25-foot Walk (25FTW) 17 is a test of ambulatory function, requiring the patient to walk 25 feet quickly and safely in his or her usual manner. The Nine-hole Peg Test (9HPT) 17, 19 measures arm and hand function -the patient moves nine pegs from a box into nine holes on a peg board, then back into the open box twice with each hand. The time is averaged for each hand. The
Three-second Paced Auditory Serial-addition Task (PASAT3) 17, 20 measures cognitive function. Patients listen to a series of 61 spoken numbers with three seconds between each, and must add each number to the previous number. The score is the number of correct additions out of 60.
The MSFC score is reported as a standardised z-score because the three components are in different units of measurement (seconds and number correct) and direction of change (improvement is indicated by higher PASAT scores but lower 25FTW and 9HPT scores). A z-score is created for each component by standardising to a reference population and the z-scores for the 25FTW and 9HPT are transformed such that a decrease represents worsening. Finally, the z-scores from the three tests are averaged to create the final MSFC score. 21 The reference population might be the baseline study population or a standard external reference population, such as that of the task force pooled data set. 17 Lower MSFC scores compared with baseline suggest neurologic deterioration.
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Reliability
The MSFC has excellent reliability, but practice effects have been demonstrated. A pilot study of 10 patients with secondary progressive MS assessed the reliability of the MSFC through administration of six sessions of the MSFC over a two-week period. 22 The first five sessions were conducted by the same technician, whereas another technician administered the sixth session. The intraclass correlation coefficient between session four and five was 0.97, demonstrating excellent intra-rater reliability. The intraclass correlation coefficient between session five and six was 0.95, again demonstrating excellent inter-rater reliability, which was maintained six months later. 22 There were similar findings of excellent reliability in a larger phase III trial. The MSFC was used as the primary efficacy end-point in the phase III International Multiple Sclerosis Secondary Progressive Avonex Controlled Trial (IMPACT). 23 Before randomisation, the 436 patients underwent three pre-baseline MSFC testing sessions. The MSFC had excellent intra-rater reliability, with an intraclass correlation coefficient of 0.90 for session three (final pre-baseline session) and session four (baseline session). 23 Both studies demonstrated practice effects with the MSFC. Although these effects were evident initially, the MSFC scores stabilised by the fourth administration. 22, 23 Practice effects were most apparent with the 9HPT, followed by the PASAT, whereas there were no practice effects for the 25FTW after the first administration. 24 Thus, it has been suggested that there should be one pre-baseline administration of the 25FTW, three pre-baseline administrations of the PASAT and four pre-baseline administrations of the 9HPT to maximise efficiency. Impact Profile (SIP) in 300 patients with MS. The physical components of both the SF-36 and SIP were more strongly correlated with the MSFC than the mental and psychosocial components of these instruments. 28 Predictive criterion validity is the ability of an instrument to predict future disease status. Support for this form of validity was provided by a follow-up study of the phase III study of intramuscular interferon beta−1a (IFNβ-1a; Avonex ® ). 5 In 160 patients it was found that MSFC scores from this clinical trial strongly predicted MSFC and MRI status
Multiple Sclerosis Inteferon Beta-1a
The MSFC was first used as a primary outcome measure in a phase III placebo-controlled study of IFNβ-1a in secondary progressive MS (IMPACT). 31 The median MSFC z-score change was reduced by 40.4%
in IFNβ-1a patients compared with placebo, whereas there was no benefit demonstrated by the EDSS. 31 These findings suggest that the MSFC is more sensitive to change in disability than is the EDSS.
Interferon Beta-1b
The MSFC was used as a secondary outcome measure in the phase III trial of Betaseron in newly emerging MS for initial treatment (BENEFIT). 32 Patients with a clinically isolated syndrome, including a first neurologic event and two or more clinically silent MRI lesions, were given either subcutaneous IFNβ-1b (Betaseron ® ) or placebo every other day for two years or until they developed MS. They were then eligible to enter a follow-up study involving continuing IFNβ-1b or switching from placebo to IFNβ-1b for three additional years to assess whether early treatment had an effect on disability progression. Early treatment had a beneficial effect on six-month-confirmed EDSS disability progression three years after the initial neurologic event,
suggesting that a treatment delay early in the course of disease affects later disability accumulation. However, the MSFC did not detect any relevant deterioration in either group and there was no difference between groups in their overall scores. The investigators were surprised by this finding because the MSFC was designed to improve sensitivity to change compared with the EDSS. However, the authors concluded that the MSFC might not be suitable in measuring disability early during the course of disease because domains not included in the MSFC (i.e. visual and sensory function) are often more affected in early MS than are those domains measured by the MSFC (i.e. arm dexterity, ambulation and cognition).
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The MSFC was also used as a secondary outcome measure in a randomised placebo-controlled pilot trial of IFNβ-1b in 73 patients with primary progressive or transitional MS. There was no difference between groups in disability progression as measured by the EDSS;
however, there was a significant difference in MSFC scores favouring
IFNβ-1b, 34 suggesting better sensitivity of the MSFC in this study.
Glatiramer Acetate
The MSFC was used as a secondary disability end-point in a large placebo-controlled trial of glatiramer acetate (Copaxone ® ) in primary progressive MS (PROMiSE). 35 Changes in both the MSFC and EDSS score were not significantly different in the placebo or treatment groups, and the study was terminated early. . 7 Natalizumab reduced disability progression compared with the placebo as measured by both the EDSS and MSFC. There was a significant difference in MSFC z-score change from baseline apparent after 12 weeks of treatment, which was maintained over two years. 36 The MSFC was also used as a secondary efficacy end-point in the trial of natalizumab plus IFNβ-1b versus IFNβ-1b alone (The Safety and efficacy of antegren in combination with IFNβ-1a in subjects with relapsing-remitting MS
[SENTINEL] trial). 8 Similarly, the natalizumab-treated group had a reduced risk of disability progression as measured by the EDSS and MSFC compared with IFNβ-1b alone. There was a significant difference between groups in the MSFC z-score change from baseline that was apparent 48 weeks after beginning natalizumab and sustained over two years. 
Clinical Relevance of the Multiple Sclerosis Functional Composite
To interpret MSFC scores in both clinical trials and individual patients, it is important to understand meaningful changes in the MSFC. It has been suggested that a 20% change in the 25FTW and 9HPT represents a reliably true change in function, whereas lower levels of change might represent clinically insignificant day-to-day fluctuations. 37 In addition, it has been suggested that an increase of more than 20%
in the 25FTW or 9HPT also indicates a clinically significant impact on disability, as perceived by patients with MS. [38] [39] [40] However, the clinically relevant change in the overall MSFC score has not yet been determined. 41 This limits the usefulness of the MSFC as an outcome
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measure. Additionally, the MSFC z-score value is not clinically useful and it is neither practical or beneficial to incorporate the MSFC routinely into clinical practice.
Multiple Sclerosis Functional Composite versus Expanded Disability Status Scale
The MSFC was originally developed to improve or supplement the EDSS as a measure of disability, given flaws identified in the EDSS.
There are several technical issues that favour one scale over the other, which are discussed below. The single biggest limitation of the MSFC is the fact that a given score tells a clinician nothing about how a patient with MS appears from a neurologic perspective, which the EDSS does do. As such, the MSFC is less informative for clinicians and, therefore, is used far less than the EDSS, which is a widely used disability end-point in clinical trials of MS. Although there are advantages of the MSFC, there are also several additional limitations to its use, as discussed below.
The main advantage of the MSFC is that it is a quantitative linear continuous measure with high reliability and validity. By contrast, the EDSS is an ordinal scale and deterioration is non-linear with a ceiling effect. 2 It has been suggested that, given its continuous nature, the MSFC is more sensitive to change in disability than is the EDSS. 17 This is supported by a study that showed that the MSFC had better precision than did the EDSS in detecting differences in MS severity based on MRI findings, however overall both the EDSS and MSFC correlated weakly with MRI pathology. 42 Additionally, the MSFC measures a broader range of MS dimensions than does the EDSS, with inclusion of measurements of cognitive and arm function, rather than the sole reliance on ambulation at high EDSS scores. 17 However, despite including these dimensions, the MSFC lacks measures of visual function, sensory function and fatigue, which are also important dimensions of MS. 17 It has been suggested that contrast letter acuity would be a useful addition to the MSFC as a measure of visual function. 43 Another quoted advantage of the MSFC is that it can be administered by a trained staff member rather than a neurologist, which has been suggested to be cost effective and more practical than the neurologist-administered EDSS. 44 However, clinical trials generally still include the EDSS, with the MSFC as an additional measure rather than a replacement. Thus, the argument of lowering costs by implementing the MSFC is problematic. 45 The MSFC progression is more useful and clinically meaningful than is the MSFC z-score change, and is more similar to the way that EDSS data are currently used in clinical trials.
Multiple Sclerosis 
Conclusions
The MSFC is a multidimensional objective measure of neurologic function that was developed to be a more sensitive measure of disability than the EDSS for use as a clinical trial disability end-point.
The MSFC has excellent intra-and inter-rater reliability. 22, 23 Validity of the MSFC has also been demonstrated; the MSFC correlates well with EDSS, MRI measures of disease, and quality of life measures. 17, 23, [25] [26] [27] [28] Since its development, the MSFC z-score change has been used as a secondary disability end-point in clinical trials. [32] [33] [34] [35] 7, 8, 10, 11 The MSFC is a linear, quantitative continuous measure that may be more sensitive to detect changes in disability than the ordinal EDSS scale. 2, 17, 42 Additionally, it measures a broader range of disability, including cognitive and arm function in addition to ambulation.
However, it does not include a measure of visual function. 17 Other limitations include significant practice effects with the 5HPT and PASAT 3 components 24 and the use of varying reference populations affects MSFC scores and limits comparability between studies. 17 Although a 20% change in components of the MSFC has been suggested to be clinically meaningful, 37 clinical interpretation of MSFC z-score change remains unclear, 41 which limits the use of the MSFC as a primary outcome measure in clinical trials. An alternative approach to analysing MSFC data has recently been suggested to improve the clinical interpretation of this scale. This involves defining MSFC progression based on a three-month period of sustained worsening by 15 or 20% in at least one MSFC component, rather than using MSFC z-score change. 45 Currently, the most widely accepted end-points in MS clinical trials are relapse rate and disability progression measured using the EDSS. With further study, the newly defined MSFC progression could be used as a primary disability outcome measure in future clinical trials. n
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